
News|Articles|October 28, 2026
FAQ: What should clinicians know about congenital measles?
Author(s)Contemporary Pediatrics Staff
Fact checked by: Morgan Ebert, Executive Editor
Missed the AAP's new congenital measles guidance? This easy-to-read FAQ covers what pediatric clinicians need to know.
Advertisement
Advertisement
The American Academy of Pediatrics (AAP) has released new guidance in Red Book Online on congenital measles, developed in response to ongoing US measles outbreaks and a resulting increase in congenital measles cases nationwide. The resource, published September 8, 2026, addresses how congenital measles is defined, how it presents, how affected neonates should be evaluated and managed, infection prevention and control, long-term follow-up, and prevention.
Related to this article

A meta-analysis of 7 real-world studies found maternal RSVpreF 78% effective against RSV LRTI hospitalization in infants up to 6 months.

The US lost measles elimination status after 26 years; CDC and partners plan to regain it via MMR vaccination and $100M in health department funding.

US preterm birth rate held at 10.4%, earning a fifth straight D+ from March of Dimes; maternal deaths fell, but racial disparities persist.

CDC data show pediatric CP-CRE incidence rose 92% from 2019 to 2024, driven by NDM-CRE, mostly in children with complex medical needs.

Julie Sweetland, PhD, shares strategies to improve vaccine conversations by explaining the science, acknowledging parental concerns, and building trust.

In 5.2 million US infants, newborn vitamin K nonreceipt rose to 6.8% by 2025 and was tied to a 47% higher bleeding risk by 6 months.

New real-world data reveal delays and disparities in nirsevimab administration, highlighting opportunities to improve timely RSV protection for infants.
Advertisement
Advertisement

